Arno Ylitalo

Bexmarilimab plus azacitidine for high-risk myelodysplastic syndrome and relapsed or refractory acute myeloid leukaemia: results from the dose-escalation part of a multicentre, single-arm, phase 1/2 trial (2025)

The Lancet Haematology

Kontro, Mika; Stein, Anthony Selwyn; Pyörälä, Marja; Rimpiläinen, Johanna; Siitonen, Timo; Ylitalo, Arno; Fjällskog, Marie-Louise; Jalkanen, Juho; Aakko, Sofia; Pawlitzky, Inka; Hollmén, Maija; Daver, Naval

(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )

Secreted Clever-1 modulates T cell responses and impacts cancer immunotherapy efficacy (2025)

Theranostics

Prince, Stuart; Viitala, Miro; Sjoroos, Riikka; Bendes, Abris a.; Rannikko, Jenna H.; Patten, Daniel A.; di Benedetto, Ilaria; Turpin, Rita; Ylitalo, Arno; Tyni, Laura; Figueiredo, Carlos R.; Bostrom, Pia; Koskivuo, Ilkka; Salminen, Tiina A.; Shetty, Shishir; Hollmen, Maija

(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )

CLEVER-1 targeting antibody, bexmarilimab, supports HLA-DR expression and alters ex vivo responsiveness to azacitidine and venetoclax in myeloid malignancies (2025)

Scientific Reports

Aakko, Sofia; Ylitalo, Arno; Kuusanmäki, Heikki; Rannikko, Jenna H.; Björkman, Mari; Mandelin, Jami; Heckman, Caroline A.; Kontro, Mika; Hollmén, Maija

(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )

Arno

Ylitalo

Contact

Publications

Sort by:

Bexmarilimab plus azacitidine for high-risk myelodysplastic syndrome and relapsed or refractory acute myeloid leukaemia: results from the dose-escalation part of a multicentre, single-arm, phase 1/2 trial (2025)

Secreted Clever-1 modulates T cell responses and impacts cancer immunotherapy efficacy (2025)

CLEVER-1 targeting antibody, bexmarilimab, supports HLA-DR expression and alters ex vivo responsiveness to azacitidine and venetoclax in myeloid malignancies (2025)